Clinical Study to Establish the Feasibility and Usability of the EndoRings™

Colorectal Cancer Clinical Trial

Official title:

EndoRings™ - Clinical Protocol

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01868971
• Other study ID #: CSDPR100
• Status: Completed
• Phase: N/A
• First received: May 29, 2013
• Last updated: July 26, 2017
• Start date: April 2013
• Est. completion date: October 2013

Study information

• Verified date: July 2017
• Source: EndoAid
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this prospective clinical study is to establish the feasibility and usability of the ENDORINGS™ when used during standard colonoscopy procedure.

Description:

The EndoAid Ltd. EndoRings is used during endoscopy procedures. The EndoRings is a short silicon rubber tube with flexible circular wings that attaches to the distal end of the endoscope to facilitate endoscopic therapy.

The EndoRings is designed to fit specific endoscopes (as designated on the packaging), and is supplied sterile following ETO sterilization and is single use only.

Indications for Use:

To be attached to the distal end of the endoscope to facilitate endoscopic therapy, to be used for the following:

• Keeping the suitable depth of endoscope's view field

• Helping the endoscope with being inserted into the gastrointestinal tract

Patient Population: The study population is comprised of patients indicated for colonoscopy.

Study Design: Single-center study. A single treatment group of 60 patients. No. of Patients:

Up to sixty (60) treated patients will be enrolled in the study.

Primary Endpoints:The primary endpoint is reaching the cecum of the colon with the ENDORINGS™.

Secondary Endpoints / Other Outcomes:

1. Incidence of complications (number of complications)

2. Ability to complete s therapeutic interventions as biopsies, polypectomies, APC etc.

3. Procedure time.

4. Ease of scope insertion, advancement and withdrawal.

5. Ability to center the scope inside the gastrointestinal tract.

6. Subjective evaluation of the additional area screened by the physician (recorded in the source documents by a questionnaire).

7. Patient satisfactory (by a follow up phone-call in which questionnaire with VAS scale will be filled out).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: October 2013
• Est. primary completion date: October 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

Any subject who meets all of the following criteria may be included in this study:

• Subject between the ages of 18 and 70

• The patient is undergoing colonoscopy for screening, or for surveillance in follow-up of previous polypectomy or for diagnostic workup;

• Written informed consent must be available before enrollment in the trial

• For women with childbearing potential, adequate contraception

Exclusion Criteria:

Any subject who meets any of the following criteria will not be included in this study:

• Patients with a history of colonic resection;

• Patients with inflammatory bowel disease;

• Patients with a personal history of polyposis syndrome;

• Patients with suspected chronic stricture potentially precluding complete colonoscopy;

• Patients with diverticulitis or toxic megacolon;

• Patients with a history of radiation therapy to abdomen or pelvis;

• Patients who are currently enrolled in another clinical investigation in which the intervention might compromise the safety of the patient's participation in this study.

Related Conditions & MeSH terms

• Bowel Cancer
• Colon Cancer
• Colorectal Cancer
• Colorectal Neoplasms

Intervention

Device:
• EndoRings
Colonoscopy procedure, standard endo-therapy interventions will be performed in accordance with physician`s evaluation

Locations

Country	Name	City	State
Israel	Elisha Medical Center	Haifa	Please Select

Sponsors (1)

Lead Sponsor	Collaborator
EndoAid

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary endpoint is reaching the cecum of the colon with the ENDORINGS™.		24 hours post procedure
Secondary	1. Incidence of complications (number of complications)	Known complications include: Perforation; Severe abdominal pain; Infection; Bleeding (other than expected minor bleeding due to therapeutic procedures e.g. polypectomy); Inducing inflammation of diverticulum; Arrhythmia, bradycardia, hypotension, hypoxia; Death A complication is defined as any one of the above complications as well as any other unexpected complication requiring medical intervention beyond that of the standard procedure. All adverse events will be reported and treated as per the standard clinical practices.; A telephone call should be made to the patient at 24 hour post- procedure, to assess post-examination adverse events.	24 hours post procedure
Secondary	2. Ability to complete s therapeutic interventions as biopsies, polypectomies, APC etc.	Whenever a polyp or other abnormality is detected, the endoscopist will perform biopsy, polypectomy or other evaluation or therapy as appropriate. The clinical investigator will use his/her clinical judgment on the safety of polyp removal/biopsy.	24 hours post procedure
Secondary	3. Procedure time.	Procedural times for each colonoscopy procedure: Time for intubation to the cecum; Time for withdrawal from the cecum to the anal verge; Total procedure time	During procedure
Secondary	4. Ease of scope insertion, advancement and withdrawal.	Physician`s subjective evaluation will be recorded in the source documents by a questionnaire.	During procedure
Secondary	5. Ability to center the scope inside the gastrointestinal tract.	Physician`s subjective evaluation will be recorded in the source documents by a questionnaire.	During procedure
Secondary	6. Subjective evaluation of the additional area screened by the physician.	Physician`s subjective evaluation will be recorded in the source documents by a questionnaire.	During procedure
Secondary	7. Patient satisfactory.	A telephone call should be made to the patient at 24 hour post- procedure, to assess patient satisfactory by completing a VAS scale questionnaire.	During procedure